The biopharmaceutical company focused on the ‘biology of healing’ has announced the completion of the enrolment of the adult patient population (50 adult patients) in its pivotal IVIG (Intravenous Immunoglobulin) phase III clinical trial for the treatment of primary immunodeficiency diseases (“PIDD”). Completion of the pediatric cohort of 25 children is anticipated to complete shortly. Five months ahead of target, this potentially brings forward a major revenue stream
